Across TCGA pan-cancer cohorts, KIFBP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KIFBP data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher KIFBP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIFBP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and LUSC are the cancer types where KIFBP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.104	0.950	<.001	34	view →
UCEC	DFS	Median	All	1.000	0.628	.020	18	view →
LUSC	OS	Median	All	0.184	0.679	<.001	15	view →
COAD	OS	Median	All	0.650	0.875	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KIFBP tumor-vs-normal RNA expression · all KIFBP data types